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Transcutanous aortic valve replacement 
with Medtronic CoreValve in a public-
private partnership hospital complex
both death and hospitalisation. Reported 30 day mortality ranges 
from 5 - 15%(9-13) with 1 year survival ranging from 60 - 80%.(8,10,14-16) 
Improvement in symptomatology and valvular hemodynamic were 
also sustained at 2 years of follow-up.(10,13,16) The long-term durability 
of TAVI valves still has to be ascertained, but the 3 - 5 year results 
are promising.(15) Initial results with the Medtronic CoreValve device 
(Medtronic Inc. Minneapolis, USA) were inferior to those of the 
rival device. Increasing experience revealed a trend of improved 
combined safety endpoints.(17) Recent results from the ADVANCE 
registry have shown procedural success rate of 98%, with 6 month 
and 1 year survival rates being 88% and 82% respectively.(18)
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ABSTRACT
TAVI
INTRODUCTION
In the developed world, aortic stenosis (AS) is the most frequent 
type of valvular heart lesion found in the elderly. It primarily pre-
sents as calcific aortic stenosis in adults of advanced age above 
65 years.(1,2) In asymptomatic individuals with severe AS, average 
event-free survival at 2 years ranges from 20 - 50%. However, in 
symptomatic patients the prognosis is dismal with survival rates of 
15 - 50% at 5 years.(3-5)
Aortic valve replacement is the definitive therapy for severe AS. 
However, many patients with AS and coexisting conditions are 
not candidates for surgical aortic valve replacement. In the Euro 
Heart Survey 33% of 216 patients >75 years presenting with 
symptomatic severe AS were not referred for surgery.(6) Trans-
catheter aortic valve implantation (TAVI) is an alternative, less 
invasive treatment for high risk patients with symptomatic severe 
AS. In the absence of anatomical contraindications, transfemoral 
approach is the preferred access route with a procedural success 
rate of >95%.(7-10) In selected patients, TAVI reduced the rates of 
Objective: The aim of this study was to assess the initial 
experience of transcutaneous aortic valve implantation 
(TAVI) in a high risk aortic stenosis population not suitable 
for conventional surgical valve replacement.
Background: No data exist for TAVI with Medtronic 
CoreValve in South Africa and especially not in a public 
private partnership hospital complex.
Methods: Retrospective data regarding severe aortic 
stenosis evaluation, risk stratifi cation and management 
were evaluated over a 24 month period.
Results: A total of 106 patients were evaluated of whom 
17 were accepted for surgical valve replacement (SVR) 
while TAVI was attempted in 25. The CoreValve was 
successfully implanted in 96% (24/25) of the cases. No 
procedural or peri-procedural deaths occurred. Three 
patients required permanent pacemaker insertion in the 
peri-procedural period and 2 patients had vascular access 
complications requiring blood transfusion only. Median 
hospital stay was 3.7days (range: 2 - 7).  Aortic valve gradient 
showed a signifi cant reduction after valve implantation, 
which was sustained during follow-up (p<0.001). NYHA 
class symptomatology also improved from a median of 
3.3 to 1.0 (p<0.001). During follow-up there were 4 late 
deaths, not related to the procedure, occurring after 78 to 
193 days. Average cost for private and government patients 
were R268 000.00 and R163 000.00 respectively.
Conclusions: The CoreValve can be implanted with a high 
success rate. Short term mortality and morbidity are 
acceptable. Signifi cant symptomatic improvement is gained 
at follow-up. The fi nancial implications are important.
SAHeart 2013;10:526-531
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Recommendations regarding the use of TAVI have been proposed 
in a recent expert consensus document.(19) These guidelines 
recommend that TAVI only be attempted in severe symptomatic 
AS, unsuitable for surgery as assessed by a multi-disciplinary heart 
team and in hospitals with cardiac surgery facilities on-site.
Universitas Netcare is a Public Private Partnership Hospital com-
plex which forms part of the University of the Free State Medical 
School of Health Sciences. The aim of this study is to report on the 
prevalence of aortic stenosis and initial experience with the 
Medtronic CoreValve. 
METHODS
The TAVI programme in our hospital was initiated in 2011. A 
dedicated multi-disciplinary TAVI team was assembled consisting of 
2 cardiologists, 2 cardiothoracic surgeons, an anesthetist (with TAVI 
experience), 2 radiologists, 2 echocardiographers, 2 catheterisation 
laboratory trained senior nurses and 2 radiographers. Between 
January 2011 and January 2013 transthoracic echocardiographic 
(TTE) data from patients with significant aortic or mitral valvular 
lesions (aortic stenosis valve area <1cm2, mitral stenosis valve area 
<1.2cm2 and aortic or mitral regurgitation with left ventricular 
dilatation) were assessed. Patients older than 20 years with aortic 
stenosis were assessed for TAVI or surgical valve replacement 
(SVR) on clinical and TTE data. Patients who were considered for 
TAVI, in addition, all had trans esophageal echocardiography (TEE), 
contrast aortic and outflow tract computerised tomography (CT) 
scanning as well as cardiac catheterisation.TTE and TEE were done 
utilising Philips Sonographic Model I E 33. Measurements were 
done in long axis, 4 chamber and short axial views. The CT scan 
(GE 750 HD 64 slice Dual Energy) utilises a multi-planar oblique 
tool to create a double oblique transverse or axial image of the 
aortic root. Axial images of the aortic annulus are essential because 
the aortic annulus and coronary sinus are non cylindrical structures. 
A dedicated hardware programme (Heart Navigator, Koninklijke 
Philips Electronics, N.V) was used to allow for different CoreValve 
sizes to be superimposed on the aortic annulus thus optimising 
valve selection of appropriate size. Routine blood tests, according 
to the recommended TAVI protocol, were done. Additive and 
Logistic Euro and Society of Cardiothoracic Risk (STS) scores were 
calculated and frailty assessed. A final decision regarding TAVI 
eligibility and SVR ineligibility was made by the multi-disciplinary 
team. In this regard age, co-morbid conditions, frailty, Euro and STS 
scores were taken into account. This was then discussed with the 
patient and fully informed consent was obtained. An agreement 
was concluded between the Academic Provincial Health Authority 
and Medtronic Inc. (Minneapolis, USA) regarding financial funding 
in patients without private medical benefit funding. In patients 
with medical funding benefit, authorisations were obtained on an 
ad hoc basis from the medical funders.
TAVI procedure was performed as described by Grube, et al.(20) 
and the first 22 patients’ procedures were carried out under 
guidance of a proctor. The standard protocol allows for pre-
procedural balloon valvuloplasty (BVP) followed by CoreValve 
self expanding placement and no deviation from this approach 
occurred. In all patients the procedure was done under general 
anesthesia and vascular access was gained through the trans femoral 
approach. In 24 patients a Prostar (Abbott laboratories, Illinois, 
USA) closure device was used and in 2 surgical exploration. The 
first 22 procedures were done under guidance of a proctor with 
extensive experience in TAVI procedure.
RESULTS 
Between January 2011 and January 2013, a total of 1 043 patients 
with significant valvular lesions were defined by means of TTE 
(Figure 1). Of these, 106 (10.1%) had significant AS. Age distribu-
tion showed that 37.7% and 62.3% respectively were older or 
younger than 75 years. Eight patients were lost to follow-up. 
Subsequently a total of 98 patients (54 male and 44 female) with 
significant AS and a mean age 59.7 years (36 - 89 years) were 
evaluated for TAVI and SVR. Of these 14 were considered unsuit-
able for both TAVI and SVR. Seventeen patients (mean age 55 
years, ranging from 40 - 73 years) had SVR. The average hospital 
Death
n = 9
TAVI
n = 26
CoreValue
n = 24
Funding issues
n = 26
FIGURE 1:  Aortic valve stenosis evaluation and outcome
Significant AS
n = 106
Unsuitable: SVR or TAVI
n = 14
Lost to follow-up
n = 8
SVR
n = 17
Postponed
n = 6
AS = aortic stenosis; SVR = surgical valve replacement; TAVI = transcatheter aortic valve 
implantation.  
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stay was 11 days and 2 died during the peri-operative period. Nine 
patients (average age 76 years) died while awaiting TAVI pro-
cedure. Of these, 5 died during hospitalisation (average hospi-
talisation period 11 days) and 4 at home. Inadequate financial 
funding (9 government and 17 private) in 26 patients (19 male and 
7 female, mean age 76 years) was the reason for delay in the TAVI. 
In 6 patients TAVI procedure was postponed as the degree of AS 
was considered to be non critical. 
Twenty six patients (14 males and 12 females, median age 82.3 
years; range 63 - 88 years) were evaluated for possible TAVI. Of 
these, 16 were private and 10 public sector patients. All patients 
were symptomatic with median NYHA class symptoms of 3.3. 
Median Logistic Euro and STS scores predicted 52.0% and 19.4% 
mortality rates respectively. The co-morbid conditions reflect 
on these calculations. Two patients experienced palpitations, 5 
patients had had previous syncopal or presyncopal attacks, while 
7 other patients complained of angina like symptoms. Co-morbid 
conditions were present in the form of COPD and pulmonary 
hypertension in 10 patients, concomitant significant coronary artery 
disease in 10, previous aortic tissue valve replacement in 3 and 
impaired renal function (creatinine >140mmol/l) in 4 patients. 
Renal function was acceptable (average creatinine = 102.7, range 
59 - 195mmol/l). Pre-procedural pro BNP values were markedly 
elevated with a median value of 1154pg/ml. Pre-procedural echo-
cardiographic, cardiac catheterisation and computerised tomo-
graphic data are shown in Table 1.
Balloon valvuloplasty with a Nucleus Balloon (NuMED, Hopkinton, 
NY, USA) size ranging from 18 - 25mm was done before CoreValve 
placement in 22 patients. In 3 patients with previous tissue SVR, 
balloon valvuloplasty was not attempted. Both BVP and valve 
placement was done during short bursts of rapid ventricular pacing 
at a rate of 120 - 160 beats per minute. In 1 patient aortic valve 
measurement after BVP was indicative of insignificant residual AS 
(transvalvular gradient <10mmHg) and no further attempt at valve 
replacement was undertaken. In our experience the residual 
transvalvular gradient following BVP is >30mmHg thus explaining 
the position taken not to continue with CoreValve placement.
CoreValve placement with intention to treat was done in 25 
patients and implanted in 24 (96% success) using 26mm, 29mm 
and 31mm valves in 10, 9 and 5 patients respectively. Average 
contrast volume used, procedural and screening time was 139ml, 
92 minutes and 46 minutes respectively. In 1 patient CoreValve 
placement was unsuccessful as a result of valve displacement into 
the left ventricular cavity. The valve was retrieved, but due to 
technical issues the valve was eventually placed in the descending 
aorta. No further attempt at secondary valve placement was 
undertaken. Post-procedural echocardiographic and hemodynamic 
data can be viewed in Figures 2 and 3.
Median post-procedural stay in the intensive care unit (ICU) was 
96 hours. No decline in renal function occurred in the peri-
procedural period with average creatinine being 99.7mmol/l at 
discharge. In the 4 patients with pre-procedural elevated creatinine 
no further deterioration occurred after the procedure. All patients 
were discharged directly from the ICU. Post procedural compli-
cations occurred in 5 patients before discharge. Three patients 
developed complete atrioventricular dissociation and permanent 
pacemaker insertion was needed. In 2 patients blood transfusion 
was required. In one of these, the fall in hemoglobin was related 
to femoral bleeding from the contra lateral puncture site for 
additional arterial and venous access required for temporary 
pacemaker placement. In another, bleeding from the access site 
closed by means of the Prostar device (Abott laboratories, Illinois, 
USA) occurred and was treated using conservative measures only.
In an attempt to calculate the private cost component of TAVI, 
total individual hospital fees were obtained from the private hospital 
finance division. An average value was the calculated. Average 
government patient cost was obtained from Universitas Academic 
public sector hospital finance division according to the individual 
account of each patient should such an individual have been 
classified as a private paying patient. According to the finance 
division such figures reflect the actuarial cost in the public sector. 
Average total (CoreValve, delivery system, disposables, hospitali-
sation and permanent pacemaker if needed) procedural cost for 
medical aid funded patients was R268 414.00. The corresponding 
amount for government funded patients was R163 203.00. No 
professional fees could be charged for government patients. The 
difference in procedural costs can largely, but not only be ascribed 
TAVI
TABLE 1:  Echocardiographic, catheterisation and CT 
measurements of the aorta
 Echo Cath CT
Gradient (mmHg) 41 (23 - 86) 55 (24 - 123) 
Ava (cm2) 0.6 (0.3 - 0.9) 0.6 (0.3 - 0.8) 
Annulus (mm) 23 (19 - 30) 23 (18 - 30) 24 (20 - 31)
Cor sinus (mm)  31 (21 - 39) 33 (28 - 40)
ST junction (mm) 25 (15 - 32) 26 (17 - 35) 28 (22 -35)
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to the special financial arrangement concluded regarding CoreValve 
cost between Medtronic and the Universitas Academic public 
sector component of the private public partnership complex in 
Bloemfontein. TAVI, in both groups of patients, were done in 
the same shared cardiac catheterisation theatre according to the 
local private public partnership agreement. Post-procedural care 
however took place in different government and private onsite 
intensive care units.
Patients were followed up for a period ranging from 3 - 15 months. 
There were 4 deaths. Of these, 3 had previous tissue SVR prior to 
TAVI. One male patient demised due to severe chronic obstructive 
airways disease with severe respiratory failure (day 80 after TAVI). 
One urinary incontinent male patient developed E.coli septicaemia 
without echocardiographic evidence of infective endocarditis and 
died 94 days after implantation. A female patient with a history of 
major depression died after 5 months because of failure to thrive 
but with apparent improvement in cardiac symptomatology noted 
during initial follow-up at 30 days. Death occurred in a male patient 
related to septicaemia as a result of gangrenous involvement of 
the left lower leg (non procedural site) 7 months post-procedure. 
The patient was treated in another hospital and according to the 
treating surgeon was in a stable cardiac condition. According to 
this communication, and also the fact that death occurred seven 
months post-procedure, we have no reason to suspect that this 
was related to the TAVI procedure. None of these deaths occurred 
in patients who required permanent pacemaker insertion. Late 
complete heart block (n = 1) occurred 16 days after the proce-
dure and required permanent pacemaker. All surviving patients at 
months 6 to 15 experienced substantial symptomatic improve-
ment. Echocardiographic ejection fraction was unchanged but 
New York Heart Association class improved significantly from a 
median of 3.3 to 1.0 (p<0.001)(Figure 4). Pro BNP values decreased 
to a median value of 495pg/ml (p=0.3).
FIGURE 2:  Hemodynamic data before and after TAVI
Peak to peak (PTP) pressure gradients immediately before and 
after valve implantation (mmHg).
Pre Post
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(m
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p <0.0001
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FIGURE 3:  Echocardiographic (TTE)  aortic valve gradient 
pre and post TAVI
Routine (awake) peak instantaneous gradient (PIG) on transthoracic 
echocardiography before (pre) TAVI implantation and at fi rst 
follow-up visit (post) 30 days following procedure.
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FIGURE 4:  NYHA
New York heart association grading of exercise capability before 
TAVI and at fi rst follow-up visit.
Pre Follow-up
N
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A
p <0.0001
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0
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DISCUSSION
In our institution severe aortic stenosis represents 10.1% of all 
significant valvular lesions. Demographically, our study population 
included both first and third world individuals and subsequently 
showed a predominant age distribution less than 75 years which 
differs noticeably from experience in developed countries where 
patients are much older.(1,2) In a geriatric population symptoma-
tology may be difficult to interpret, but it is significant that only a 
minority of patients presented with classical symptoms of angina, 
syncope or palpitations. Our data have confirmed the adverse 
outcome of aortic stenosis if treated medically.(3) Many such patients 
die in hospital with obvious subsequent financial implications. 
At present selection criteria for TAVI favour an already high risk 
population for both morbidity and mortality. The expected survival 
rates for healthy geriatric patients aged 65, 75, 85 and 95 are 15, 10, 
5 and 3 years respectively.(21) Corresponding statistics for patients 
with severe aortic stenosis are unavailable. In a high risk geriatric 
population it is thus impossible to draw conclusions regarding 
impact on mortality and morbidity if treated by means of TAVI. 
Long term benefits after 10 years will, however, unlikely differ 
from conventional surgical valve replacement. For the foreseeable 
future SVR will be the treatment of choice in low risk patients and 
TAVI will be offered to moderate or high risk and relatively elderly 
patients.(22)
In our experience, TAVI is a technically demanding interventional 
cardiologic procedure with a challenging learning curve and initial 
proctor guidance is a non-negotiable necessity. A multi-disciplinary 
approach towards patient selection was very meaningful. From a 
practical perspective, computerised tomography of the aortic valve 
was the most valuable method for determining CoreValve size 
prior to implantation. This was related to axial reconstruction of 
the aortic annulus and coronary sinuses and utilisation of the dedi-
cated hardware programme. The programme allows for different 
valve sizes to be superimposed on aortic annular reconstructions in 
axial, sagittal and coronal planes. This represents a huge advantage 
over TEE, TTE and contrast angiography. Our success rate with the 
Medtronic CoreValve system compares favourably with previous 
data.(7-9,12,18) Rapid ventricular pacing is helpful during both BVP and 
valve deployment. Particular care was taken to limit screening 
time but despite this it was still more than 30 minutes which is 
not unexpected in view of the challenging nature of the proce-
dure and our initial inexperience. Although contrast volume used 
was high, renal function was unaffected. Total procedural time 
was acceptable.
Post-procedural intensive care stay was remarkably short. This 
certainly had an influence on  procedural cost. Although aortic 
stenosis is a primary medical benefit (PMB) condition, private 
medical funders at present reimburse only for medical therapy and 
SVR as management modalities. Their position is based on the 
view that present day scientific data regarding the merit of TAVI, 
as opposed to SVR, are inadequate and that it is not a financially 
viable option. Also, the fact that in our country TAVI is not available 
in the public sector precludes them from refunding TAVI even 
though AS is a PMB. Our data certainly refute the notion that TAVI 
is unavailable in the public sector. The council of medical schemes 
has in individual disputed cases advised that TAVI be reimbursed to 
the amount of R330 000.00. Their position in such financial disputes 
was that this amount is an estimated reflection of the 
costs for SVR in the private sector. Figures obtained from a major 
hospital group (personal communication not to be revealed) 
showed an average cost for all complicated SVR procedures (78%) 
amounting to R266 691.00 for 2012. TAVI cost in private medical 
aid funded patients in our experience was comparable to this 
amount. The cost difference between private and public funded 
patients reflects on the financial agreement reached between 
Medtronic Company and the academic public sector authorities in 
our center.
The incidence of peri-procedural complications in the form of 
atrioventricular conduction disturbance was not different from 
previously reported data.(9,10,12,18) At 3 - 15 months follow-up, mor-
tality rates were also comparable to other studies.(12,13,15,16) Our 
experience regarding short term mortality for valve-in-valve TAVI 
differs from other data.(23, 24) In 47 patients reported by Webb, et al. 
the success rate was 98% with 30 day mortality of 17%. In 3 out of 
8 fatalities non cardiac septicaemia was reported. In our limited 
experience none of the deaths were cardiac related but in 2 
patients underlying non cardiac septicaemia was noted. Also, post-
procedural death occurred much later in our patients. The signi-
ficance of post-procedural septicaemia in this patient group pro-
bably warrants further investigation.  In all the remaining patients, 
symptomatic improvement was noted. The declines in pro BNP 
values were substantial, although not significant but the small patient 
cohort may have had an influence on this result.    
CONCLUSIONS
TAVI is technically, logistically and financially a very demanding 
procedure. Our initial experience with Medtronic CoreValve TAVI 
was acceptable with a good immediate success and low complica-
tion rate. The favourable procedural financial implications are 
important. Present day guidelines regarding patient selection to 
include only patients in the highest 10th percentile of risk preclude 
meaningful long term outcome assessment.(25)
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